Rae Lyn Burke

US Patent:

6635258, Oct 21, 2003

Filed:

May 26, 1998

Appl. No.:

09/084669

Inventors:

Rae Lyn Burke - San Francisco CA
Michael A. Tigges - Oakland CA

Assignee:

Chiron Corporation - Emeryville CA

International Classification:

A61K 3900

US Classification:

4242311, 4241851, 4242041, 4242291, 530350

Abstract:

Vaccines containing herpes simplex virus (HSV) VP22 polypeptides capable of eliciting a cellular immune response and methods for treating and preventing HSV infections using the vaccines are disclosed. The vaccines can include additional HSV polypeptides, such as HSV glycoproteins. Also disclosed are methods of DNA immunization.

US Patent:

7138505, Nov 21, 2006

Filed:

Aug 13, 1990

Appl. No.:

07/569376

Inventors:

George Kuo - San Francisco CA, US
Frank Masiarz - San Francisco CA, US
Martha Truett - Oakland CA, US
Pablo Valenzuela - San Francisco CA, US
Mirella Ezban Rasmussen - Copenhagen, DK
Daniel Caput - San Francisco CA, US
Rae Lyn Burke - San Francisco CA, US
Carol Pachl - Oakland CA, US

Assignee:

Novartis Vaccines and Diagnostics, Inc. - Emeryville CA

International Classification:

C07H 21/02
C07H 21/04
C12N 15/00
C12N 15/09
C12N 15/63
C12N 15/70
C12N 15/74
A01N 43/04
A61K 31/70

US Classification:

536 231, 424 931, 4243201, 514 44, 536 245, 536 234

Abstract:

Methods and compositions are provided for recombinant DNA production of Factor VIIIC and truncated derivatives thereof. Based on amino acid sequences, probes are developed for isolating messenger RNA, cDNA and/or chromosomal DNA encoding for Factor VIIIC. The Factor VIIIC gene in its entirety, a fragment thereof, or a cDNA is then used for expression of Factor VIIIC in a host. The bacteriophage λFVIII23D containing the 14. 43 kb EcoRI fragment was deposited at the A. T. C. C. on Jan. 4, 1984 and given Accession No. 40094. Also, the vector pSVF8-200 was deposited at the A. T. C. C. on Jul. 17, 1985 and given Accession No. 40190.

US Patent:

7592021, Sep 22, 2009

Filed:

Oct 3, 2005

Appl. No.:

11/242680

Inventors:

Gita Natarajan Shankar - Saratoga CA, US
Rae Lyn Burke - San Francisco CA, US

Assignee:

SRI International - Menlo Park CA

International Classification:

A61K 9/00

US Classification:

424484

Abstract:

Formulations and methods for transmucosal delivery of a beneficial agent are described in which a pH-responsive component and a temperature-responsive component are combined and applied to a mucous membrane. The temperature-responsive component is a component that, in aqueous solutions, is capable of undergoing a temperature-dependent sol to gel phase transition. The formulations may be characterized as having bioadhesive properties, and are suitable for delivery of a variety of beneficial agents.

US Patent:

20010016340, Aug 23, 2001

Filed:

Dec 22, 2000

Appl. No.:

09/748062

Inventors:

Barbara Chapman - Berkeley CA, US
Rae Burke - San Francisco CA, US
Mirella Rasmussen - Copenhagen, DK
Jan Mikkelson - Gentofte, DK

Assignee:

Chiron Corporation and Novo Nordisk A/S

International Classification:

C12P021/04
C07H021/04

US Classification:

435/069600, 435/217000, 536/023200

Abstract:

Recombinant protein complexes having human Factor VIII:C activity are expressed in a eukaryotic host cell by transforming the host cell with first and second expression cassettes encoding a first polypeptide substantially homologous to human Factor VIII:C A domain and a second polypeptide substantially homologous to human Factor VIII:C C domain, respectively. In the present invention, the first polypeptide may be extended having at its C-terminal a human Factor VIII:C B domain N-terminal peptide, a polypeptide spacer of 3-40 amino acids, and a human Factor VIII:C B domain C-terminal peptide. Expression of the second polypeptide is improved by employing an -antitrypsin signal sequence.

US Patent:

20030170825, Sep 11, 2003

Filed:

Sep 26, 2002

Appl. No.:

10/256849

Inventors:

Barbara Chapman - Berkeley CA, US
Rae Burke - San Francisco CA, US
Mirella Rasmussen - Copenhagen, DK
Jan Mikkelson - Gentofte, DK

Assignee:

Chiron Corporation

International Classification:

C12P021/04
C07K014/775

US Classification:

435/069600, 435/320100, 435/325000, 530/383000

Abstract:

Recombinant protein complexes having human Factor VIII:C activity are expressed in a eukaryotic host cell by transforming the host cell with first and second expression cassettes encoding a first polypeptide substantially homologous to human Factor VIII:C A domain and a second polypeptide substantially homologous to human Factor VIII:C C domain, respectively. In the present invention, the first polypeptide may be extended having at its C-terminal a human Factor VIII:C B domain N-terminal peptide, a polypeptide spacer of 3-40 amino acids, and a human Factor VIII:C B domain C-terminal peptide. Expression of the second polypeptide is improved by employing an -antitrypsin signal sequence.

US Patent:

20040137579, Jul 15, 2004

Filed:

Dec 1, 2003

Appl. No.:

10/726199

Inventors:

Barbara Chapman - Berkeley CA, US
Rae Burke - San Francisco CA, US
Mirella Rasmussen - Copenhagen, DK
Jan Mikkelson - Gentofte, DK

International Classification:

C12P021/04
C07K014/755

US Classification:

435/069600, 435/320100, 435/325000, 530/383000

Abstract:

Recombinant protein complexes having human Factor VIII:C activity are expressed in a eukaryotic host cell by transforming the host cell with first and second expression cassettes encoding a first polypeptide substantially homologous to human Factor VIII:C A domain and a second polypeptide substantially homologous to human Factor VIII:C C domain, respectively. In the present invention, the first polypeptide may be extended having at its C-terminal a human Factor VIII:C B domain N-terminal peptide, a polypeptide spacer of 3-40 amino acids, and a human Factor VIII:C B domain C-terminal peptide. Expression of the second polypeptide is improved by employing an -antitrypsin signal sequence.

US Patent:

20060122376, Jun 8, 2006

Filed:

Nov 30, 2005

Appl. No.:

11/290051

Inventors:

Barbara Chapman - Berkeley CA, US
Rae Burke - San Francisco CA, US
Mirella Rasmussen - Copenhagen, DK
Jan Mikkelson - Gentofte, DK

Assignee:

Chiron Corporation - Emeryville CA

International Classification:

C12P 21/04
C12N 5/06
C12N 5/08
C07H 21/04

US Classification:

530383000, 435069600, 435364000, 435358000, 435367000, 536023500, 435354000

Abstract:

Recombinant protein complexes having human Factor VIII:C activity are expressed in a eukaryotic host cell by transforming the host cell with first and second expression cassettes encoding a first polypeptide substantially homologous to human Factor VIII:C A domain and a second polypeptide substantially homologous to human Factor VIII:C C domain, respectively. In the present invention, the first polypeptide may be extended having at its C-terminal a human Factor VIII:C B domain N-terminal peptide, a polypeptide spacer of 3-40 amino acids, and a human Factor VIII:C B domain C-terminal peptide. Expression of the second polypeptide is improved by employing an .alpha.sub.1-antitrypsin signal sequence.

US Patent:

57892032, Aug 4, 1998

Filed:

Jun 27, 1994

Appl. No.:

8/266170

Inventors:

Barbara Chapman - Berkeley CA
Rae Lyn Burke - San Francisco CA
Mirella Ezban Rasmussen - Copenhagen, DK
Jan Moller Mikkelson - Gentofte, DK

Assignee:

Chiron Corporation - Emeryville CA
Novo Nordisk A/S - Bagsvaerd

International Classification:

C07K 14755
C12N 510
C12N 1512
C12N 1563

US Classification:

435 696

Abstract:

Recombinant protein complexes having human Factor VIII:C activity are expressed in a eukaryotic host cell by transforming the host cell with first and second expression cassettes encoding a first polypeptide substantially homologous to human Factor VIII:C A domain and a second polypeptide substantially homologous to human Factor VIII:C C domain, respectively. In the present invention, the first polypeptide may be extended having at its C-terminal a human Factor VIII:C B domain N-terminal peptide, a polypeptide spacer of 3-40 amino acids, and a human Factor VIII:C B domain C-terminal peptide. Expression of the second polypeptide is improved by employing an. alpha. sub. 1 -antitrypsin signal sequence.